Grant Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
	Jan. 13, 2022	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities			$ 197,580		$ 197,580		$ 489,090
Other current assets			13,000		13,000
VIR Biomedical Advanced Research and Development Authority | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			11,800		26,100
Human Immunodeficiency Virus ('HIV') Grant | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant awarded amount. maximum			65,700		65,700
Vaccinal Antibody Grant | Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue from grants			4,700	$ 2,100	6,600	$ 4,600
Vaccinal Antibody Grant | Bill And Melinda Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Deferred revenue			15,700		15,700		15,500
Accrued and other liabilities			7,600		7,600		$ 7,700
BARDA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential maximum amount of grant		$ 1,000,000
Maximum amount of grant during the base period		$ 55,000
Potential Future Reimbursement			$ 2,500		$ 2,500